Monte Rosa Therapeutics GLUE
NASDAQ GLUE
$11.22 -0.14 (-1.23%)
At close: Oct 21, 2026 · 4:00 PM EDT

Monte Rosa Therapeutics (GLUE) EV to CFO (2024 - 2025)

Updated

Monte Rosa Therapeutics' EV to CFO came in at 2.70 for Q3 2025, down 75.2% from the prior quarter.

Analysis

Monte Rosa Therapeutics (GLUE) EV to CFO (2024 - 2025) Analysis & Trends

Over the trailing twelve months to Sep 30, 2025, Monte Rosa Therapeutics reported EV to CFO of 0.20; for FY2024, it was 4.82.

  • Business Quant data shows GLUE's EV to CFO at 10.87 (Q2 2025), 8.73 (Q1 2025) and 4.82 (Q4 2024) in the three quarters before Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Monte Rosa Therapeutics 1.14 Bn 550.40 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 2.70
Jun 30, 2025 10.87
Mar 31, 2025 8.73
Dec 31, 2024 4.82
API Access

Monte Rosa Therapeutics EV to CFO API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ev-to-cfo&ticker=GLUE&period=max&api_key=YOUR_API_KEY